Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Strategies to improve checkpoint blockade tumour immunotherapy
FY 2015-16
Summary
Checkpoint blockade tumour immunotherapy is aimed at re-awakening the anti-tumour immune response by antagonizing receptor-ligand interactions that are responsible for suppressing anti-tumour T cell activity. For example, monoclonal antibody (mAb) targeting of cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), leads to killing of tumour-infiltrating regulatory T cells and boosts endogenous cytotoxic T cell responses against tumours. Phase III clinical trials with Ipilimumab, a fully human anti-CTLA-4 mAb, is clinically effective in approximately 15% of metastatic melanoma patients1. Recently Roman et al. demonstrated a strong correlation between circulating numbers of patrolling monocytes (pMo) and the therapeutic outcome following anti-CTLA-4 therapy. Mechanistically, pMos are thought to catalyze the depletion of immunosuppressive T cell populations within tumours in a manner that depends on pMo Fc receptor expression and the isotype of the therapeutic mAbs. We hypothesise that the efficacy of existing and new checkpoint blockade immunotherapies could be improved by increasing the number of circulating pMos. We will test this hypothesis using both Lyn tyrosine kinase loss- and gain-of-function mouse mutants, since we have recently discovered that Lyn acts as a critical regulator of pMo homeostasis. Together my proposed studies promise to provide new insights into the biology of this newly described subset of monocytes and may lead to strategies to improve existing and new checkpoint blockade cancer immunotherapies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349849
Name
Frias Da Silva Jessica A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Strategies to improve checkpoint blockade tumour immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Cytotoxic T-Lymphocyte Associated Antigen 4; Antibody-Dependent Cell-Mediated Cytotoxicity; Cancer; Immunotherapy; Monoclonal Antibodies; Patrolling Monocytes
Abstract
Checkpoint blockade tumour immunotherapy is aimed at re-awakening the anti-tumour immune response by antagonizing receptor-ligand interactions that are responsible for suppressing anti-tumour T cell activity. For example, monoclonal antibody (mAb) targeting of cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), leads to killing of tumour-infiltrating regulatory T cells and boosts endogenous cytotoxic T cell responses against tumours. Phase III clinical trials with Ipilimumab, a fully human anti-CTLA-4 mAb, is clinically effective in approximately 15% of metastatic melanoma patients1. Recently Roman et al. demonstrated a strong correlation between circulating numbers of patrolling monocytes (pMo) and the therapeutic outcome following anti-CTLA-4 therapy. Mechanistically, pMos are thought to catalyze the depletion of immunosuppressive T cell populations within tumours in a manner that depends on pMo Fc receptor expression and the isotype of the therapeutic mAbs. We hypothesise that the efficacy of existing and new checkpoint blockade immunotherapies could be improved by increasing the number of circulating pMos. We will test this hypothesis using both Lyn tyrosine kinase loss- and gain-of-function mouse mutants, since we have recently discovered that Lyn acts as a critical regulator of pMo homeostasis. Together my proposed studies promise to provide new insights into the biology of this newly described subset of monocytes and may lead to strategies to improve existing and new checkpoint blockade cancer immunotherapies.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Frias Da Silva, Jessica A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~